Published 8 days ago • loading... • Updated 8 days ago

Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveo

Perfuse Therapeutics announced on May 6, 2025, that PER-001 improved vision and eye structure in glaucoma patients after a single intravitreal dose in a Phase 2a trial in San Francisco.
This announcement follows growing concern over glaucoma, a leading cause of irreversible blindness affecting about four million Americans, with prevalence expected to double within 15 years.
PER-001 showed safety, sustained release, validated target engagement via the endothelin pathway, improved ocular blood flow, and increased retinal nerve fiber layer thickness at 24 weeks.
The high-dose group improved visual field mean deviation by +1.5 dB per year, while low dose increased RNFL thickness by +7.7 microns per year, with CEO Gurkan calling the data 'very promising.'
Perfuse plans a pivotal Phase 2b adaptive trial in the second half of 2025 to advance PER-001 as the first disease-modifying glaucoma therapy amid unmet medical needs.

Insights by Ground AI

Does this summary seem wrong?

27 Articles

All

Left

Center

Right

Tucson

+25 Reposted by 25 other sources

Center

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks –

8 days ago·Tucson, United States

Read Full Article

Eyewire+

Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveo

Iantrek announced it has surpassed 2,000 AlloFlo Uveo procedures in the US. The key milestone comes ahead of its full commercial launch planned for this fall during the American Academy of Ophthalmology 2025 meeting. Recent momentum has been fueled by the publication of 2-year safety and efficacy data and the American Academy of Ophthalmology's new reimbursement endorsement for cyclodialysis with scleral reinforcement, which the company says sol…

8 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year